We describe DDFP distribution in brain, kidney, liver, spleen, and lung following nine dosing regimens in New Zealand White (NZW) rabbits. The total clearance of DDFP was consistent with previous reports showing 98% of DDFP is cleared within 2 h of administration.
DDFPe was injected into rabbits and blood samples were taken over time. A 2-compartment model was the best fit to the DDFP blood concentration-time profiles in each of the animals tested. A rapid distribution phase followed by a longer elimination phase was observed. In this species, the distribution phase half-life was 1.15 ± 0.6 min while the elimination half-life was 13.5 ± 11 min (N=4) Dated: 2015
Very high doses of DDFP were injected into New Zeland white rabbits. DDFP promptly reaches the brain and concentrations rise in all tissues with multiple doses. Future studies will develop a dosing regimen to optimize a wide range of therapeutic effects in ischemic states and minimize toxicity. Dated: 2014
The purpose of this study was to prospectively study the human pharmacokinetics of an ultrasound (US) contrast agent through its active ingredient, dodecafluoropentane (DDFP). In expired air, DDFP concentration exhibited a biexponential decay. The percentage of recovery was 98 +/- 19% at 2 h. No extraneous peaks were observed, indicating no detectable DDFP metabolites. It was concluded that DDFP pharmacokinetics in blood fitted to an open one-compartment model with a fast elimination half-life. Recovery in expired air was almost complete 2 h after administration. Dated: 2001